Idéal Investisseur Connexion Connexion
Français English
CAC 40 : Market closed
7 927,75 pts
-1.89%


Last updated : 20/11/2026 - 17h35 (last close)
Last close data
🏠 Home   ➤    Stock news

Bastide to Sell Experf to Sapio to Accelerate Debt Reduction

Bastide Group has signed a purchase agreement for the sale of its subsidiary New Medical Concept, the holding company of the Experf group, which specializes in home infusion and nutrition, to Sapio Group. This cash transaction will allow the group to crystallize the value created since the acquisition of Experf in 2017 and to continue its debt reduction.


Bastide to Sell Experf to Sapio to Accelerate Debt Reduction

A Subsidiary with an Established Growth Profile

Experf, integrated into Bastide Group in 2017, recorded a turnover of approximately 18 million euros with more than 15 locations in France at that time. For the 2024-2025 fiscal year, the group operates a network of 28 agencies and generated a turnover of 42 million euros, reflecting a doubling of its activity due to the development of its territorial network and the strengthening of its teams. The sale is part of Bastide Group's asset management strategy and optimization of its business portfolio.

Financial Impact and Maintenance of 2025-2026 Objectives

This cash transaction will allow for continued debt reduction and a decrease in financial expenses. The financial leverage ratio (post IFRS 16) is expected to be slightly above 2.5x post-transaction, compared to 2.77x as of December 31, 2025. Given the expected date of deconsolidation, this sale will not have a significant impact on the published revenue for the current fiscal year (ending June 30, 2026), with the target maintained at at least 510 million euros and an operating margin around 9.0%.

Completion Conditions and Advisory Support

The completion of the transaction remains subject to customary suspensive conditions, particularly related to the information-consultation of the Social and Economic Committee. Oddo BHF acted as the exclusive financial advisor for Bastide Group, ADVANT Altana as legal counsel, while Sapio Group was advised by Goodwin Procter LLP as legal counsel and Eight Advisory for financial and tax advice. Marsh supported the due diligence in insurance matters.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Dispositifs médicaux et optique › Dispositifs médicaux


Context

Period
  • Period: T1 2027
Key reported figures
  • Revenue: 124,3 millions d'euros
  • Quarterly revenue: 124,3 millions d'euros
  • Revenue growth: 7,5 %
Guidance from the release
  • The Group's Q1 performance confirms the strength of its business momentum and its full confidence in achieving its full-year targets
Opportunities identified
  • International markets showing very strong momentum with growth of nearly 20%, driven by Oxystore Italy and Intus UK performances
  • Diabetes business recorded growth of more than 20% with positive volume and pricing effects
  • Respiratory care maintained strong momentum at 10.6% growth supported by structural market growth and market share gains
Outlook / guidance
  • Expected revenue: 500 millions d'euros

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours